Company logo

ICPT - Intercept Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
New York, United States
Type: Equity

ICPT price evolution
ICPT
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Jan 2023
Current assets
Cash $103.66 $137.36 $63.02 $55.86
Short term investments $219.98 $277.63 $372.19 $435.05
Net receivables $32.48 $29.79 $28.75 $26.86
Inventory $2.65 $6.27 $6.46 $6.46
Total current assets $383.44 $470.77 $490.46 $540.13
Long term investments
Property, plant & equipment $0.82 $0.91 $0.9 $6.11
Goodwill & intangible assets
Total noncurrent assets $9.72 $13.87 $13.63 $13.58
Total investments $219.98 $277.63 $372.19 $435.05
Total assets $393.16 $484.63 $504.08 $553.71
Current liabilities
Accounts payable $89.49 $73.68 $95.19 $14.23
Deferred revenue
Short long term debt $109.81 $109.69 $109.57
Total current liabilities $90.84 $187.02 $207.12 $230.08
Long term debt $223.86 $223.6 $223.35 $223.1
Total noncurrent liabilities $230.47 $230.07 $229.78 $230.56
Total debt $223.86 $333.41 $333.04 $332.67
Total liabilities $321.32 $417.09 $436.9 $460.63
Shareholders' equity
Retained earnings -$2177.68 -$2174.89 -$2169.02 -$2136.89
Other shareholder equity -$7.2 -$7.62 -$7.62 -$8.26
Total shareholder equity $71.84 $67.55 $67.19 $93.08
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $55.86 $94.41 $65.65 $74.78
Short term investments $435.05 $334.98 $411.52 $582.57
Net receivables $26.86 $47.62 $41.55 $38.04
Inventory $6.46 $8.62 $9.03 $8.46
Total current assets $540.13 $502.29 $545.74 $721.32
Long term investments
Property, plant & equipment $6.11 $3.38 $6.33 $5.2
Goodwill & intangible assets
Total noncurrent assets $13.58 $24.73 $34.75 $33.57
Total investments $435.05 $334.98 $411.52 $582.57
Total assets $553.71 $527.02 $580.49 $754.89
Current liabilities
Accounts payable $14.23 $158.22 $171.04 $153.97
Deferred revenue
Short long term debt $109.57
Total current liabilities $230.08 $166.82 $179.08 $162
Long term debt $223.1 $539.78 $560.58 $532.08
Total noncurrent liabilities $230.56 $544.17 $568.27 $541.33
Total debt $332.67 $539.78 $560.58 $532.08
Total liabilities $460.63 $710.99 $747.34 $703.33
Shareholders' equity
Retained earnings -$2136.89 -$2489.77 -$2398.35 -$2123.47
Other shareholder equity -$8.26 -$2.87 -$2.48 -$1.14
Total shareholder equity $93.08 -$183.96 -$166.85 $51.56
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue $88.79 $83.72 $67.96 $77.22
Cost of revenue $0.2 $0.18 $0.22 $0.03
Gross Profit $88.59 $83.53 $67.74 $77.19
Operating activities
Research & development $41.51 $37.31 $41.71 $39.89
Selling, general & administrative $45.44 $53.35 $57.66 $55.29
Total operating expenses $93.21 $90.65 $99.37 $95.18
Operating income -$4.62 -$7.12 -$31.63 -$17.98
Income from continuing operations
EBIT -$0.99 -$3.05 -$29.33 -$18.02
Income tax expense
Interest expense $1.8 $2.81 $2.81 $2.81
Net income
Net income -$2.79 -$5.86 -$32.13 -$20.82
Income (for common shares) -$2.79 -$5.86 -$32.13 -$20.82
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $285.71 $363.47 $312.69 $252
Cost of revenue $0.98 $3.1 $5.32 $4.21
Gross Profit $284.73 $360.37 $307.37 $247.79
Operating activities
Research & development $176.64 $185.27 $191.49 $242.8
Selling, general & administrative $176.3 $230.85 $332.49 $317.42
Total operating expenses $352.94 $416.04 $538.61 $560.22
Operating income -$68.22 -$55.67 -$231.24 -$312.43
Income from continuing operations
EBIT $243.2 -$37.01 -$226.83 -$303.54
Income tax expense
Interest expense $21.39 $54.42 $48.05 $41.14
Net income
Net income $221.82 -$91.43 -$274.88 -$344.68
Income (for common shares) $221.82 -$91.43 -$274.88 -$344.68
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$2.79 -$5.86 -$32.13 -$20.82
Operating activities
Depreciation -$0.51 $0.44 $0.35 $0.33
Business acquisitions & disposals
Stock-based compensation $6.65 $6.26 $5.86 $5.23
Total cash flows from operations $16.69 -$23.3 -$51.6 -$4.81
Investing activities
Capital expenditures -$0.01 -$0.1 $0.3
Investments $59.79 $96.97 $65.55 -$55.23
Total cash flows from investing $59.77 $96.95 $59.32 -$54.94
Financing activities
Dividends paid
Sale and purchase of stock $0.05 $0.01 $0.01 $1.25
Net borrowings -$110.02 -$6.85
Total cash flows from financing -$110 -$0.04 -$0.25 -$5.67
Effect of exchange rate -$0.17 $0.74 -$0.31 $1.1
Change in cash and equivalents -$33.7 $74.34 $7.16 -$64.32
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income $221.82 -$91.43 -$274.88 -$344.68
Operating activities
Depreciation $2.26 $8.76 $9.26 $9.05
Business acquisitions & disposals
Stock-based compensation $21.89 $33.89 $60.85 $55.98
Total cash flows from operations -$26.78 -$41.64 -$170.03 -$236.61
Investing activities
Capital expenditures -$0.57 -$0.4 -$3.89 -$1.14
Investments -$100.82 $71.12 $166.71 -$187.85
Total cash flows from investing $261.85 $70.73 $162.82 -$188.99
Financing activities
Dividends paid
Sale and purchase of stock $1.68 -$75.81 $1.3 $236.25
Net borrowings -$268.44 -$38.13 $223.42
Total cash flows from financing -$267.32 $1.12 -$0.69 $457.52
Effect of exchange rate -$6.3 -$1.45 -$1.22 -$0.39
Change in cash and equivalents -$38.55 $28.75 -$9.13 $31.53
Fundamentals
Market cap $794.42M
Enterprise value $914.62M
Shares outstanding 41.81M
Revenue $317.68M
EBITDA -$50.77M
EBIT -$51.38M
Net Income -$61.61M
Revenue Q/Q 14.44%
Revenue Y/Y -3.83%
P/E ratio -12.89
EV/Sales 2.88
EV/EBITDA -18.01
EV/EBIT -17.80
P/S ratio 2.50
P/B ratio 10.05
Book/Share 1.89
Cash/Share 2.48
EPS -$1.47
ROA -12.73%
ROE -82.24%
Debt/Equity 4.95
Net debt/EBITDA -4.29
Current ratio 4.22
Quick ratio 4.19